BTIG raised the firm’s price target on Organogenesis (ORGO) to $9 from $7 and keeps a Buy rating on the shares. With the changes in reimbursement set to take effect in 2026, there will be clear share winners and share losers, and the firm believes that Organogenesis will be one of those that may be a share winner based on its current product pricing structure relative to the finalized pricing structure at $127.28 per cm, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORGO:
- Organogenesis Holdings Surpasses Revenue Guidance Amid Challenges
- Organogenesis Holdings Reports Record Revenue, Raises Guidance
- Organogenesis Holdings’ New Study on Diabetic Foot Ulcers: A Potential Game-Changer?
- Buy Rating for Organogenesis Holdings Despite Mixed Trial Results, Supported by Diversified Revenue and FDA Clearance Efforts
- Organogenesis Holdings Faces Setback in ReNu Phase 3 Trial